drugset
Drugs / MIL62
last change Jul 2026 re-read 2 minutes ago

MIL62

Monoclonal antibody

Developed for
B-cell non-Hodgkin lymphoma · indolent B-cell non-Hodgkin lymphoma · systemic lupus erythematosus · idiopathic membranous glomerulonephritis · lupus nephritis · membranous glomerulonephritis
Investigated by
Beijing Mabworks Biotech Co., Ltd. · Beijing InnoCare Pharma Tech Co., Ltd.

Trials 9 · a red edge is where a trial was stopped

today NCT07405970 · Ph 3 NCT05862233 · Ph 3 NCT05796206 · Ph 2 NCT05398653 · Ph 1/2 NCT07044115 · Ph 1/2 NCT04834024 · Ph 3 NCT04304040 · Ph 1/2 NCT04110301 · Ph 1/2 NCT04103905 · Ph 1
2017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04103905 Feb 2017 → May 2019 B-cell non-Hodgkin lymphoma Beijing Mabworks Biotech Co., Ltd. Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT05398653 Feb 2022 → Mar 2025 idiopathic membranous glomerulonephritis Beijing Mabworks Biotech Co., Ltd. Completed No outcome recorded
Phase 1/2 NCT07044115 Nov 2021 → Jan 2025 overdue lupus nephritis Beijing Mabworks Biotech Co., Ltd. Active not recruiting No outcome recorded
Phase 1/2 NCT04304040 Jul 2020 → Dec 2025 B-cell non-Hodgkin lymphoma Beijing InnoCare Pharma Tech Co., Ltd. Unknown No outcome recorded
Phase 1/2 NCT04110301 Nov 2019 → Jan 2024 overdue indolent B-cell non-Hodgkin lymphoma Beijing Mabworks Biotech Co., Ltd. Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT05796206 May 2023 → Feb 2026 overdue systemic lupus erythematosus Beijing Mabworks Biotech Co., Ltd. Active not recruiting No outcome recorded
Phase 33 trials
Phase 3 NCT07405970 Apr 2026 → Dec 2028 expected systemic lupus erythematosus Beijing Mabworks Biotech Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT05862233 Jun 2023 → May 2025 overdue membranous glomerulonephritis Beijing Mabworks Biotech Co., Ltd. Active not recruiting No outcome recorded
Phase 3 NCT04834024 Jun 2021 → Mar 2025 overdue indolent B-cell non-Hodgkin lymphoma Beijing Mabworks Biotech Co., Ltd. Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as MIL62 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04304040 ↗
8

NCT05862233 ↗

NCT04103905 ↗

NCT07044115 ↗

NCT05398653 ↗

NCT05796206 ↗

NCT07405970 ↗

NCT04110301 ↗

NCT04834024 ↗
Modality Monoclonal antibody “Recombinant Humanized Monoclonal Antibody MIL62 Injection” NCT04103905 ↗
Route Intravenous “Each patient received an intravenous infusion of MIL62” NCT04103905 ↗